Currently, the first-generation mTOR inhibitors (rapalogs) are used in clinical trials for treating HCC but do not show the expected efficacy; combining mTOR inhibition with sorafenib enhanced the antitumoral effect in cancer models, including HCC56. This evidence concerns the gene MTOR and hepatocellular carcinoma.